aTyr Pharma, Inc. ATYR
0.31
(0.03)
(8.82%)
as of 25 Sep
- Market cap
- $31.4M
- P/E
- 0.0×
Follow ATYR
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (98.67%) | (105.62%) | (108.11%) | (103.49%) |
+8 more TTM periods Free account |
|
| (70.97%) | (79.17%) | (78.09%) | (75.78%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(119.01%) | (116.49%) | (106.87%) | (91.88%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 34.07 | |
Free Cash Flow per Share |
(0.56) | (0.60) | (0.67) | (0.65) | |
Free Cash Flow |
(54.81) | (59.29) | (62.07) | (63.00) | |
Capital Expenditures |
(0.27) | (0.20) | (0.08) | (0.08) | |
Piotroski F-Score |
— | — | — | 4.00 | |
| Other line items | |||||
Cash ROIC |
(51.43%) | (47.49%) | (42.39%) | (36.87%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 7.77 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 551.38% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 154.83% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 40.85% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.90 | 0.84 | 0.84 | 0.84 | |
Depreciation/Fixed assets |
0.07 | (0.01) | (0.07) | (0.20) | |
Capex/Depreciation |
(0.87) | 9.23 | 0.28 | 0.09 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.11 | |
Operating CF per Share |
(0.56) | (0.60) | (0.67) | (0.65) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (672.90%) |
Columns are period end dates